Literature DB >> 23749526

FGFR fusions in the driver's seat.

Amit J Sabnis1, Trever G Bivona.   

Abstract

Through a clinical deep sequencing protocol, Wu and colleagues have identified multiple FGFR fusion proteins in diverse cancers. Pharmacologic inhibition of FGFR suppressed the growth of FGFR fusion-positive tumor models, suggesting that these FGFR fusions are oncogenic drivers and highlighting the use of streamlined clinical sequencing efforts to identify novel, actionable driver oncoproteins in human tumors. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23749526      PMCID： PMC4988530          DOI： 10.1158/2159-8290.CD-13-0185

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

1.  FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Authors:  Lisa E S Crose; Katherine T Etheridge; Candy Chen; Brian Belyea; Lindsay J Talbot; Rex C Bentley; Corinne M Linardic
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Cancer genomics: from discovery science to personalized medicine.

Authors:  Lynda Chin; Jannik N Andersen; P Andrew Futreal
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

Review 4.  Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.

Authors:  Maria Vittoria Dieci; Monica Arnedos; Fabrice Andre; Jean Charles Soria
Journal:  Cancer Discov       Date:  2013-02-15       Impact factor: 39.397

5.  FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.

Authors:  S Xiao; S R Nalabolu; J C Aster; J Ma; L Abruzzo; E S Jaffe; R Stone; S M Weissman; T J Hudson; J A Fletcher
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

6.  Transforming fusions of FGFR and TACC genes in human glioblastoma.

Authors:  Devendra Singh; Joseph Minhow Chan; Pietro Zoppoli; Francesco Niola; Ryan Sullivan; Angelica Castano; Eric Minwei Liu; Jonathan Reichel; Paola Porrati; Serena Pellegatta; Kunlong Qiu; Zhibo Gao; Michele Ceccarelli; Riccardo Riccardi; Daniel J Brat; Abhijit Guha; Ken Aldape; John G Golfinos; David Zagzag; Tom Mikkelsen; Gaetano Finocchiaro; Anna Lasorella; Raul Rabadan; Antonio Iavarone
Journal:  Science       Date:  2012-07-26       Impact factor: 47.728

Review 7.  ALK in lung cancer: past, present, and future.

Authors:  Alice T Shaw; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

8.  Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

Authors:  James G Taylor; Adam T Cheuk; Patricia S Tsang; Joon-Yong Chung; Young K Song; Krupa Desai; Yanlin Yu; Qing-Rong Chen; Kushal Shah; Victoria Youngblood; Jun Fang; Su Young Kim; Choh Yeung; Lee J Helman; Arnulfo Mendoza; Vu Ngo; Louis M Staudt; Jun S Wei; Chand Khanna; Daniel Catchpoole; Stephen J Qualman; Stephen M Hewitt; Glenn Merlino; Stephen J Chanock; Javed Khan
Journal:  J Clin Invest       Date:  2009-10-05       Impact factor: 14.808

9.  Oncogenic FGFR3 gene fusions in bladder cancer.

Authors:  Sarah V Williams; Carolyn D Hurst; Margaret A Knowles
Journal:  Hum Mol Genet       Date:  2012-11-21       Impact factor: 6.150

10.  Identification of targetable FGFR gene fusions in diverse cancers.

Authors:  Yi-Mi Wu; Fengyun Su; Shanker Kalyana-Sundaram; Nickolay Khazanov; Bushra Ateeq; Xuhong Cao; Robert J Lonigro; Pankaj Vats; Rui Wang; Su-Fang Lin; Ann-Joy Cheng; Lakshmi P Kunju; Javed Siddiqui; Scott A Tomlins; Peter Wyngaard; Seth Sadis; Sameek Roychowdhury; Maha H Hussain; Felix Y Feng; Mark M Zalupski; Moshe Talpaz; Kenneth J Pienta; Daniel R Rhodes; Dan R Robinson; Arul M Chinnaiyan
Journal:  Cancer Discov       Date:  2013-04-04       Impact factor: 39.397
  10 in total
  5 in total

1.  A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients.

Authors:  Yi Sun; Gao Li; Wei Zhu; Qiuyan He; Yongchang Liu; Xianshan Chen; Juan Liu; Jing Lin; Han Han-Zhang; Zheng Yang; Analyn Lizaso; Jianxing Xiang; Xinru Mao; Hao Liu; Yang Gao
Journal:  Ann Transl Med       Date:  2020-10

2.  Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers.

Authors:  Libing Xiang; Jiajia Li; Wei Jiang; Xuxia Shen; Wentao Yang; Xiaohua Wu; Huijuan Yang
Journal:  Oncotarget       Date:  2015-03-10

3.  Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis.

Authors:  Benedetta Lombardi; Paul Ashford; Aurelio A Moya-Garcia; Aleksander Rust; Mark Crawford; Sarah V Williams; Margaret A Knowles; Matilda Katan; Christine Orengo; Jasminka Godovac-Zimmermann
Journal:  Oncotarget       Date:  2017-10-25

4.  The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.

Authors:  Tom D Bunney; Shunzhou Wan; Nethaji Thiyagarajan; Ludovico Sutto; Sarah V Williams; Paul Ashford; Hans Koss; Margaret A Knowles; Francesco L Gervasio; Peter V Coveney; Matilda Katan
Journal:  EBioMedicine       Date:  2015-03-01       Impact factor: 8.143

5.  SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas.

Authors:  Shanbo Zheng; Yunjian Pan; Rui Wang; Yuan Li; Chao Cheng; Xuxia Shen; Bin Li; Difan Zheng; Yihua Sun; Haiquan Chen
Journal:  Onco Targets Ther       Date:  2015-10-19       Impact factor: 4.147
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.